KRYS.O

KRYSTAL Biotech maintains a strong liquidity position, with a current ratio of 9.95 and $496.3 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure. The price-to-book ratio of 8.79 and price-to-tangible-book ratio of 8.79 reflect a premium valuation relative to its book value. In terms of profitability, KRYSTAL Biotech reported a net income of $204.8 million and an operating income of $161.3 million, with a return on equity of 16.8% and a return on assets of 15.36%. These figures are well above the industry median for profitability metrics, indicating strong operational efficiency and effective use of capital. The company's revenue is concentrated in a single therapeutic area, primarily driven by Krystexxa, with no disclosed geographic diversification in the financial data. This concentration may expose the company to risks associated with regulatory changes, product competition, or shifts in market demand for gout treatments. KRYSTAL Biotech's revenue growth trajectory is not explicitly provided in the financial data, but the company's high price-to-earnings ratio of 52.33 and price-to-revenue ratio of 26.27 suggest that the market is pricing in future growth expectations. Analysts have assigned a mean price target of $314.70, with a median of $316.50, indicating a generally positive outlook despite the high valuation. The risk assessment for KRYSTAL Biotech indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company has not issued additional shares recently, and its diluted share count is equal to its basic share count, suggesting no near-term dilution pressure. The absence of long-term debt also reduces financial risk. Recent events include the continued commercialization of Krystexxa, with no major regulatory or legal challenges reported in the latest filings. The company's focus on dermatological and autoimmune diseases remains unchanged, and there are no indications of significant strategic shifts in the near term.